Breaking News Instant updates and real-time market news.

MEDXF

Medexus Pharmaceuticals

$1.66 /

-0.055 (-3.21%)

08:50
06/06/22
06/06
08:50
06/06/22
08:50

Medexus Pharmaceuticals announces publication of study results on treosulfan

Medexus Pharmaceuticals announced that the American Journal of Hematology has accepted for publication the final study results and analysis of the pivotal phase 3 clinical trial of treosulfan conducted by medac, a strategic partner of Medexus. The publication has undergone full peer review and has already been published online. The open-label, multicenter, randomized parallel study was designed to compare event-free survival after treosulfan-based conditioning with a widely applied reduced-intensity conditioning busulfan regimen in older or comorbid patients with acute myeloid leukemia or myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation. The primary endpoint of the study was EFS of patients with disease recurrence, graft failure, or death from any cause as events. Secondary endpoints were overall survival, cumulative incidence of relapse or progression, cumulative incidence of graft failure, and non-relapse mortality. The study was performed in 31 clinical institutions across five European countries and enrolled 570 patients between June 2013 and December 2016. The publication concludes that the study demonstrates clinically relevant superiority of treosulfan over RIC busulfan with regard to its primary endpoint, EFS. The study found that EFS of patients in the study was superior after treosulfan compared to RIC busulfan. The publication also includes favorable conclusions on two key secondary endpoints, finding that overall survival with treosulfan was superior compared to busulfan and that non-relapse mortality for patients in the treosulfan arm was lower than for patients in the busulfan arm. The authors conclude that a treosulfan regimen appears particularly suitable for older AML and MDS patients. Frequencies of treatment-emergent adverse events of all grades and serious AEs were equally distributed between the study arms. Further, frequencies of patients with treatment-emergent serious AEs categorized by organ class and term were comparably low and no unknown safety risks were identified.

OTHER BREAKING NEWS FROM THE FLY

Hot Stocks
Asana reports Q3 NRR over 120% » 16:20
12/01/22
12/01
16:20
12/01/22
16:20
ASAN

Asana

$18.07 /

-0.09 (-0.50%)

The company states:…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ASAN Asana
$18.07 /

-0.09 (-0.50%)

ASAN Asana
$18.07 /

-0.09 (-0.50%)

11/28/22 JPMorgan
Asana price target lowered to $19 from $22 at JPMorgan
10/20/22 Piper Sandler
Asana price target lowered to $24 from $28 at Piper Sandler
10/13/22 KeyBanc
Asana initiated with a Sector Weight at KeyBanc
10/03/22 Morgan Stanley
Asana price target lowered to $28 from $35 at Morgan Stanley
ASAN Asana
$18.07 /

-0.09 (-0.50%)

ASAN Asana
$18.07 /

-0.09 (-0.50%)

ASAN Asana
$18.07 /

-0.09 (-0.50%)

Options
Closing CBOE SPX and VIX Index summary for December 1st » 16:20
12/01/22
12/01
16:20
12/01/22
16:20
VIX

Volatility Index S&P 500 Options

/

+

The CBOE Volatility Index…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
VIX Volatility Index S&P 500 Options
/

+

Earnings
Asana sees FY23 EPS of ($1.15) to ($1.14) , consensus ($1.25) » 16:19
12/01/22
12/01
16:19
12/01/22
16:19
ASAN

Asana

$18.07 /

-0.09 (-0.50%)

Sees FY23 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ASAN Asana
$18.07 /

-0.09 (-0.50%)

ASAN Asana
$18.07 /

-0.09 (-0.50%)

11/28/22 JPMorgan
Asana price target lowered to $19 from $22 at JPMorgan
10/20/22 Piper Sandler
Asana price target lowered to $24 from $28 at Piper Sandler
10/13/22 KeyBanc
Asana initiated with a Sector Weight at KeyBanc
10/03/22 Morgan Stanley
Asana price target lowered to $28 from $35 at Morgan Stanley
ASAN Asana
$18.07 /

-0.09 (-0.50%)

ASAN Asana
$18.07 /

-0.09 (-0.50%)

ASAN Asana
$18.07 /

-0.09 (-0.50%)

Earnings
Asana sees Q4 EPS (28c) to (27c), consensus (29c) » 16:19
12/01/22
12/01
16:19
12/01/22
16:19
ASAN

Asana

$18.07 /

-0.09 (-0.50%)

Sees Q4 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ASAN Asana
$18.07 /

-0.09 (-0.50%)

ASAN Asana
$18.07 /

-0.09 (-0.50%)

11/28/22 JPMorgan
Asana price target lowered to $19 from $22 at JPMorgan
10/20/22 Piper Sandler
Asana price target lowered to $24 from $28 at Piper Sandler
10/13/22 KeyBanc
Asana initiated with a Sector Weight at KeyBanc
10/03/22 Morgan Stanley
Asana price target lowered to $28 from $35 at Morgan Stanley
ASAN Asana
$18.07 /

-0.09 (-0.50%)

ASAN Asana
$18.07 /

-0.09 (-0.50%)

ASAN Asana
$18.07 /

-0.09 (-0.50%)

Hot Stocks
Ventyx Biosciences doses first patient in VTX958 trial » 16:18
12/01/22
12/01
16:18
12/01/22
16:18
VTYX

Ventyx Biosciences

$29.66 /

+0.81 (+2.81%)

Ventyx Biosciences…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VTYX Ventyx Biosciences
$29.66 /

+0.81 (+2.81%)

VTYX Ventyx Biosciences
$29.66 /

+0.81 (+2.81%)

11/17/22 Morgan Stanley
Ventyx Biosciences initiated with an Overweight at Morgan Stanley
10/13/22 Piper Sandler
Ventyx Biosciences named a top pick for 2023 at Piper Sandler
09/16/22 Stifel
Ventyx Biosciences price target raised to $53 from $45 at Stifel
09/13/22 H.C. Wainwright
Ventyx Biosciences price target raised to $50 from $36 at H.C. Wainwright
VTYX Ventyx Biosciences
$29.66 /

+0.81 (+2.81%)

VTYX Ventyx Biosciences
$29.66 /

+0.81 (+2.81%)

VTYX Ventyx Biosciences
$29.66 /

+0.81 (+2.81%)

Syndicate
Cigna files automatic mixed securities shelf  16:18
12/01/22
12/01
16:18
12/01/22
16:18
CI

Cigna

$323.48 /

-5.355 (-1.63%)

 
ShowHide Related Items >><<
CI Cigna
$323.48 /

-5.355 (-1.63%)

CI Cigna
$323.48 /

-5.355 (-1.63%)

11/23/22 Morgan Stanley
Walgreens Boots Alliance assumed with an Underweight at Morgan Stanley
11/23/22 Morgan Stanley
Cigna assumed with an Overweight at Morgan Stanley
11/21/22 Raymond James
Cigna downgraded to Outperform from Strong Buy at Raymond James
11/21/22 Raymond James
Cigna downgraded to Outperform from Strong Buy at Raymond James
CI Cigna
$323.48 /

-5.355 (-1.63%)

CI Cigna
$323.48 /

-5.355 (-1.63%)

CI Cigna
$323.48 /

-5.355 (-1.63%)

CI Cigna
$323.48 /

-5.355 (-1.63%)

Earnings
Asana reports Q3 EPS (26c), consensus (32c) » 16:17
12/01/22
12/01
16:17
12/01/22
16:17
ASAN

Asana

$18.07 /

-0.09 (-0.50%)

Reports Q3 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ASAN Asana
$18.07 /

-0.09 (-0.50%)

ASAN Asana
$18.07 /

-0.09 (-0.50%)

11/28/22 JPMorgan
Asana price target lowered to $19 from $22 at JPMorgan
10/20/22 Piper Sandler
Asana price target lowered to $24 from $28 at Piper Sandler
10/13/22 KeyBanc
Asana initiated with a Sector Weight at KeyBanc
10/03/22 Morgan Stanley
Asana price target lowered to $28 from $35 at Morgan Stanley
ASAN Asana
$18.07 /

-0.09 (-0.50%)

ASAN Asana
$18.07 /

-0.09 (-0.50%)

ASAN Asana
$18.07 /

-0.09 (-0.50%)

Earnings
Samsara raises FY23 EPS view to (17c)-(16c) from (23c)-(21c), consensus (21c) » 16:17
12/01/22
12/01
16:17
12/01/22
16:17
IOT

Samsara

$9.91 /

+0.39 (+4.10%)

Raises FY23 revenue view…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
IOT Samsara
$9.91 /

+0.39 (+4.10%)

IOT Samsara
$9.91 /

+0.39 (+4.10%)

09/22/22 MoffettNathanson
Samsara initiated with a Buy at MoffettNathanson
06/27/22 Goldman Sachs
Samsara downgraded to Neutral from Buy at Goldman Sachs
06/16/22 Goldman Sachs
Goldman left Samsara analyst day with stronger conviction
05/31/22 RBC Capital
Samsara price target lowered to $18 from $28 at RBC Capital
IOT Samsara
$9.91 /

+0.39 (+4.10%)

  • 15
    Dec
IOT Samsara
$9.91 /

+0.39 (+4.10%)

Earnings
Ambarella sees Q4 revenue $81M-$85M, consensus $85.39M » 16:17
12/01/22
12/01
16:17
12/01/22
16:17
AMBA

Ambarella

$73.80 /

-0.33 (-0.45%)

Sees Q4 gross margin…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AMBA Ambarella
$73.80 /

-0.33 (-0.45%)

AMBA Ambarella
$73.80 /

-0.33 (-0.45%)

11/21/22 Jefferies
Ambarella price target lowered to $96 from $104 at Jefferies
11/21/22 Stifel
Ambarella price target raised to $90 from $76 at Stifel
11/18/22 Wells Fargo
Ambarella's CV3 win a 'significant endorsement,' says Wells Fargo
10/18/22 Deutsche Bank
Ambarella price target lowered to $62 from $75 at Deutsche Bank
AMBA Ambarella
$73.80 /

-0.33 (-0.45%)

AMBA Ambarella
$73.80 /

-0.33 (-0.45%)

AMBA Ambarella
$73.80 /

-0.33 (-0.45%)

Initiation
Wedbush starts Trulieve with Outperform on broadening reach » 16:17
12/01/22
12/01
16:17
12/01/22
16:17
TCNNF

Trulieve Cannabis

$13.80 /

+0.91 (+7.06%)

Wedbush analyst Gerald…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
TCNNF Trulieve Cannabis
$13.80 /

+0.91 (+7.06%)

TCNNF Trulieve Cannabis
$13.80 /

+0.91 (+7.06%)

16:05 Today Wedbush
Trulieve Cannabis initiated with an Outperform at Wedbush
11/10/22 Canaccord
Trulieve Cannabis price target lowered to C$50 from C$54 at Canaccord
11/09/22 Bernstein
Two more states legalize cannabis, $3B added to TAM, says Bernstein
10/28/22 BTIG
Trulieve Cannabis assumed with a Buy at BTIG
TCNNF Trulieve Cannabis
$13.80 /

+0.91 (+7.06%)

Technical Analysis
NASDAQ market internals summary » 16:17
12/01/22
12/01
16:17
12/01/22
16:17
$NSD

NASDAQ Market Internals

/

+

Volume was above average…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$NSD NASDAQ Market Internals
/

+

Earnings
Samsara sees Q4 adjusted EPS (6c)-(5c), consensus (6c) » 16:16
12/01/22
12/01
16:16
12/01/22
16:16
IOT

Samsara

$9.91 /

+0.39 (+4.10%)

Sees Q4 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
IOT Samsara
$9.91 /

+0.39 (+4.10%)

IOT Samsara
$9.91 /

+0.39 (+4.10%)

09/22/22 MoffettNathanson
Samsara initiated with a Buy at MoffettNathanson
06/27/22 Goldman Sachs
Samsara downgraded to Neutral from Buy at Goldman Sachs
06/16/22 Goldman Sachs
Goldman left Samsara analyst day with stronger conviction
05/31/22 RBC Capital
Samsara price target lowered to $18 from $28 at RBC Capital
IOT Samsara
$9.91 /

+0.39 (+4.10%)

  • 15
    Dec
IOT Samsara
$9.91 /

+0.39 (+4.10%)

Initiation
Coherent initiated with a Buy at Stifel » 16:16
12/01/22
12/01
16:16
12/01/22
16:16
COHR

Coherent

$37.25 /

+0.625 (+1.71%)

Stifel analyst Ruben Roy…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
COHR Coherent
$37.25 /

+0.625 (+1.71%)

COHR Coherent
$37.25 /

+0.625 (+1.71%)

11/28/22 Deutsche Bank
Coherent upgraded to Buy from Hold at Deutsche Bank
11/11/22 BofA
Coherent upgraded to Buy at BofA on diversity, valuation
11/11/22 BofA
Coherent upgraded to Buy from Neutral at BofA
11/10/22 Craig-Hallum
Coherent price target raised to $60 from $50 at Craig-Hallum
COHR Coherent
$37.25 /

+0.625 (+1.71%)

COHR Coherent
$37.25 /

+0.625 (+1.71%)

COHR Coherent
$37.25 /

+0.625 (+1.71%)

COHR Coherent
$37.25 /

+0.625 (+1.71%)

Hot Stocks
Centrus Energy finalizes contract with DoE for uranium production » 16:16
12/01/22
12/01
16:16
12/01/22
16:16
LEU

Centrus Energy

$37.35 /

-0.64 (-1.68%)

Centrus Energy's…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
LEU Centrus Energy
$37.35 /

-0.64 (-1.68%)

LEU Centrus Energy
$37.35 /

-0.64 (-1.68%)

08/08/22 Roth Capital
Centrus Energy upgraded to Buy at Roth Capital as risks subside
08/08/22 Roth Capital
Centrus Energy upgraded to Buy from Neutral at Roth Capital
08/05/22 Lake Street
Centrus Energy upgraded to Buy at Lake Street on Inflation Reduction Act boost
08/05/22 Lake Street
Centrus Energy upgraded to Buy from Hold at Lake Street
LEU Centrus Energy
$37.35 /

-0.64 (-1.68%)

Earnings
Samsara reports Q3 adjusted EPS (2c), consensus (6c) » 16:16
12/01/22
12/01
16:16
12/01/22
16:16
IOT

Samsara

$9.91 /

+0.39 (+4.10%)

Reports Q3 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
IOT Samsara
$9.91 /

+0.39 (+4.10%)

IOT Samsara
$9.91 /

+0.39 (+4.10%)

09/22/22 MoffettNathanson
Samsara initiated with a Buy at MoffettNathanson
06/27/22 Goldman Sachs
Samsara downgraded to Neutral from Buy at Goldman Sachs
06/16/22 Goldman Sachs
Goldman left Samsara analyst day with stronger conviction
05/31/22 RBC Capital
Samsara price target lowered to $18 from $28 at RBC Capital
IOT Samsara
$9.91 /

+0.39 (+4.10%)

  • 15
    Dec
IOT Samsara
$9.91 /

+0.39 (+4.10%)

Earnings
Smartsheet sees FY23 EPS (31c) to (30c), consensus (53c) » 16:16
12/01/22
12/01
16:16
12/01/22
16:16
SMAR

Smartsheet

$32.55 /

+1.83 (+5.96%)

Sees FY23 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SMAR Smartsheet
$32.55 /

+1.83 (+5.96%)

SMAR Smartsheet
$32.55 /

+1.83 (+5.96%)

10/13/22 KeyBanc
KeyBanc bullish on Smartsheet, initiates with an Overweight
10/13/22 KeyBanc
Smartsheet initiated with an Overweight at KeyBanc
10/03/22 Morgan Stanley
Smartsheet price target lowered to $54 from $62 at Morgan Stanley
09/26/22 RBC Capital
RBC Capital positive on Smartsheet positioning, mixed on spending
SMAR Smartsheet
$32.55 /

+1.83 (+5.96%)

SMAR Smartsheet
$32.55 /

+1.83 (+5.96%)

SMAR Smartsheet
$32.55 /

+1.83 (+5.96%)

Hot Stocks
Unum Group announces $200M share repurchase authorization » 16:16
12/01/22
12/01
16:16
12/01/22
16:16
UNM

Unum Group

$41.94 /

-0.24 (-0.57%)

Unum Group announced that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
UNM Unum Group
$41.94 /

-0.24 (-0.57%)

UNM Unum Group
$41.94 /

-0.24 (-0.57%)

11/16/22 Citi
Unum Group price target lowered to $41 from $42 at Citi
11/16/22 Goldman Sachs
Unum Group downgraded to Neutral from Buy at Goldman Sachs
11/06/22 Barclays
Unum Group price target raised to $43 from $36 at Barclays
10/07/22 Truist
Unum Group price target raised to $48 from $44 at Truist
UNM Unum Group
$41.94 /

-0.24 (-0.57%)

UNM Unum Group
$41.94 /

-0.24 (-0.57%)

Earnings
Ambarella reports Q3 EPS 24c, consensus 20c » 16:16
12/01/22
12/01
16:16
12/01/22
16:16
AMBA

Ambarella

$73.80 /

-0.33 (-0.45%)

Reports Q3 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AMBA Ambarella
$73.80 /

-0.33 (-0.45%)

AMBA Ambarella
$73.80 /

-0.33 (-0.45%)

11/21/22 Jefferies
Ambarella price target lowered to $96 from $104 at Jefferies
11/21/22 Stifel
Ambarella price target raised to $90 from $76 at Stifel
11/18/22 Wells Fargo
Ambarella's CV3 win a 'significant endorsement,' says Wells Fargo
10/18/22 Deutsche Bank
Ambarella price target lowered to $62 from $75 at Deutsche Bank
AMBA Ambarella
$73.80 /

-0.33 (-0.45%)

AMBA Ambarella
$73.80 /

-0.33 (-0.45%)

AMBA Ambarella
$73.80 /

-0.33 (-0.45%)

Technical Analysis
NYSE market internals summary » 16:16
12/01/22
12/01
16:16
12/01/22
16:16
$NYE

NYSE Market Internals

/

+

Volume was above average…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$NYE NYSE Market Internals
/

+

Initiation
Lumentum initiated with a Buy at Stifel » 16:15
12/01/22
12/01
16:15
12/01/22
16:15
LITE

Lumentum

$54.27 /

-0.66 (-1.20%)

Stifel analyst Ruben Roy…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
LITE Lumentum
$54.27 /

-0.66 (-1.20%)

LITE Lumentum
$54.27 /

-0.66 (-1.20%)

11/11/22 BofA
Lumentum downgraded to Neutral at BofA on mounting headwinds
11/11/22 BofA
Lumentum downgraded to Neutral from Buy at BofA
11/09/22 B. Riley
Lumentum price target lowered to $90 from $119 at B. Riley
11/09/22 Craig-Hallum
Lumentum price target lowered to $80 from $115 at Craig-Hallum
LITE Lumentum
$54.27 /

-0.66 (-1.20%)

LITE Lumentum
$54.27 /

-0.66 (-1.20%)

Hot Stocks
LuxUrban Hotels acquires Townhouse Hotel in South Beach, FL » 16:15
12/01/22
12/01
16:15
12/01/22
16:15
LUXH

LuxUrban Hotels

$1.46 /

+0.02 (+1.39%)

LuxUrban Hotels announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LUXH LuxUrban Hotels
$1.46 /

+0.02 (+1.39%)

Initiation
Wedbush starts Curaleaf with Outperform, expects share gains » 16:15
12/01/22
12/01
16:15
12/01/22
16:15
CURLF

Curaleaf

$7.02 /

+0.4 (+6.04%)

Wedbush analyst Gerald…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CURLF Curaleaf
$7.02 /

+0.4 (+6.04%)

CURLF Curaleaf
$7.02 /

+0.4 (+6.04%)

16:04 Today Wedbush
Curaleaf initiated with an Outperform at Wedbush
11/08/22 Stifel
Curaleaf price target lowered to C$8.50 from C$9.50 at Stifel
10/28/22 BTIG
Curaleaf assumed with a Buy at BTIG
10/07/22 Stifel
Cannabis stocks could rise about three times in near-term, says Stifel
CURLF Curaleaf
$7.02 /

+0.4 (+6.04%)

CURLF Curaleaf
$7.02 /

+0.4 (+6.04%)

Earnings
Smartsheet sees Q4 EPS (2c) to 0c, consensus (9c) » 16:14
12/01/22
12/01
16:14
12/01/22
16:14
SMAR

Smartsheet

$32.50 /

+1.78 (+5.79%)

Sees Q4 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SMAR Smartsheet
$32.50 /

+1.78 (+5.79%)

SMAR Smartsheet
$32.50 /

+1.78 (+5.79%)

10/13/22 KeyBanc
KeyBanc bullish on Smartsheet, initiates with an Overweight
10/13/22 KeyBanc
Smartsheet initiated with an Overweight at KeyBanc
10/03/22 Morgan Stanley
Smartsheet price target lowered to $54 from $62 at Morgan Stanley
09/26/22 RBC Capital
RBC Capital positive on Smartsheet positioning, mixed on spending
SMAR Smartsheet
$32.50 /

+1.78 (+5.79%)

SMAR Smartsheet
$32.50 /

+1.78 (+5.79%)

SMAR Smartsheet
$32.50 /

+1.78 (+5.79%)

Hot Stocks
Sterling Construction to divest 50% stake in Myers & Sons Construction » 16:14
12/01/22
12/01
16:14
12/01/22
16:14
STRL

Sterling Construction

$32.52 /

-0.165 (-0.50%)

On November 30, 2022,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
STRL Sterling Construction
$32.52 /

-0.165 (-0.50%)

STRL Sterling Construction
$32.52 /

-0.165 (-0.50%)

Earnings
Smartsheet reports Q3 EPS (1c), consensus (15c) » 16:13
12/01/22
12/01
16:13
12/01/22
16:13
SMAR

Smartsheet

$32.61 /

+1.89 (+6.15%)

Reports Q3 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SMAR Smartsheet
$32.61 /

+1.89 (+6.15%)

SMAR Smartsheet
$32.61 /

+1.89 (+6.15%)

10/13/22 KeyBanc
KeyBanc bullish on Smartsheet, initiates with an Overweight
10/13/22 KeyBanc
Smartsheet initiated with an Overweight at KeyBanc
10/03/22 Morgan Stanley
Smartsheet price target lowered to $54 from $62 at Morgan Stanley
09/26/22 RBC Capital
RBC Capital positive on Smartsheet positioning, mixed on spending
SMAR Smartsheet
$32.61 /

+1.89 (+6.15%)

SMAR Smartsheet
$32.61 /

+1.89 (+6.15%)

SMAR Smartsheet
$32.61 /

+1.89 (+6.15%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.